Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02726633
Other study ID # CAALC-004-Prolung
Secondary ID
Status Recruiting
Phase N/A
First received March 29, 2016
Last updated April 1, 2017
Start date May 2015
Est. completion date December 2017

Study information

Verified date April 2017
Source Chinese Alliance Against Lung Cancer
Contact Chunxue Bai, MD
Phone 18621170011
Email bai.chunxue@zs-hospital.sh.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A Study to evaluate the utility of the ProLung China Test as an adjunct to CT scan in the diagnosis of lung cancer.


Description:

This Study will assess the stability of the ProLung China Test classification algorithm when used as an adjunct to CT scan. This Study will assess whether there are any potential safety concerns of the ProLung China Test when used to evaluate patients with a positive CT scan for lung cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subject is male or female, age 18 to 80.

2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions.

3. Subject's pulmonary nodule or lesion is greater than 4mm and smaller than 50mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging.

4. Subject must be able to receive a ProLung China Test within 30 days of abnormal CT within 14 days prior to the tissue biopsy or surgical resection.

Exclusion Criteria:

1. Subject has an implanted electronic device in the chest. Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis.

2. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules.

3. Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung China Test or within the previous 14 days for a bronchoscopic procedure.

4. Subject presents with an anomalous physical or anatomical condition that precludes ProLung China Test measurement.

5. Subject will have undergone unusually strenuous exercise within 24 hours.

6. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Nantong Tumor Hospital Nantong Jiangsu
China Shanghai Dongfang Hospital of Tongji University Shanghai Shanghai
China Zhongshan Hospital of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Chinese Alliance Against Lung Cancer

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Efficacy of the ProLung China Test Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. The ProLung China Test will be performed within 30 days of a CT Scan that identifies a lung lesion suspicious for lung cancer and evaluated once a patient diagnosis is obtained.
See also
  Status Clinical Trial Phase
Terminated NCT05066776 - Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
Completed NCT01958931 - Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer N/A
Recruiting NCT03528733 - Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection N/A
Recruiting NCT02693496 - Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
Completed NCT01566682 - A Multi-Center Trial of the ProLung Test™
Terminated NCT02983903 - Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions N/A
Terminated NCT02050724 - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT Phase 2
Not yet recruiting NCT04615156 - 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography Phase 3
Active, not recruiting NCT02623712 - The Watch the Spot Trial N/A
Recruiting NCT03568799 - 4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules N/A
Not yet recruiting NCT02817048 - Tubeless VATS for Peripheral Lung Nodule N/A
Recruiting NCT01149187 - Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules N/A
Completed NCT00925210 - Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach Phase 2
Completed NCT02448225 - 18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules Phase 2
Active, not recruiting NCT05171491 - LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
Terminated NCT04140474 - Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules. N/A
Withdrawn NCT05804435 - iNod™ Ultrasound-Guided Needle Biopsy System Study N/A
Not yet recruiting NCT02653859 - Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules N/A
Completed NCT02832284 - iNod System Human Feasibility Assessment N/A
Recruiting NCT02773992 - Clinical Study of Three Plus Two Type Early Diagnosis of Pulmonary Nodules in Medical Internet of Things N/A